Ipsen S.A. (0MH6.IL)

121,90 +1,40 (+1,16%) Börsenschluss: 05:34PM BST

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 5.300

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. David Loew	MD, CEO & Director	2,22M	N/A	1967
Mr. Aymeric Le Chatelier	Exec. VP & Group CFO	N/A	N/A	1969
Dr. Aidan Murphy Ph.D.	Exec. VP of Technical Operations	N/A	N/A	1966
Mr. Craig Marks	Vice-Pres of Investor Relations	N/A	N/A	N/A
Mr. Francois Garnier	Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer	N/A	N/A	1962
Ms. Gwenan White	Exec. VP of Communications, Public Affairs & Sustainability	N/A	N/A	N/A
Mr. Regis Mulot	Exec. VP & Chief HR Officer	N/A	N/A	1966
Ms. Dominique Bery	Head of Nordics & Baltics	N/A	N/A	1971
Dr. Yan Moore M.D.	Sr. VP & Head of Oncology Therapeutic Area	N/A	N/A	1967
Dr. Alexander McEwan	Vice-Pres & Head of Radiopharmaceuticals	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Corporate Governance

Ipsen S.A.s ISS Governance QualityScore, Stand 1. Oktober 2023, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 7, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.